From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer
-
ナレーター：
-
著者：
概要
While antibody-drug conjugates (ADCs) have reshaped therapeutic paradigms, the latest clinical trial results reveal a broader array of opportunities, spanning novel mechanisms of action, immunotherapy-based combinations, and molecularly targeted strategies. Through rigorous analysis of newly presented efficacy and safety data, including key PFS/OS endpoints, expert faculty will provide context and interpretation to support real-world clinical decisions. Interactive discussion will center on how these innovations are poised to reshape treatment sequencing and improve patient outcomes. This dynamic symposium will spotlight the most compelling new data presented at 2025 oncology congresses, including ASCO, ESMO GYN, and ESMO—focusing on evolving strategies for the management of advanced, platinum-resistant high-grade epithelial ovarian cancer.